| Scorecard |
|---|
|
3 / 5 Stars
|
|
Lipper
2
3
1
4
3
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
E+
(Sell)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 2.3 | 2.3 |
| Stocks | 0.0 | 0.0 |
| Bonds | 0.0 | 0.0 |
| Other | 1.28 | 1.28 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 96.42 | 96.42 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 02.28.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 02.28.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Roche Holding AG | RHHVF | 23.65 | 2.32 |
| Basf SE | BFFAF | 28.39 | 2.15 |
| Novo Nordisk A/S | NONOF | 5.13 | 2.1 |
| Msci Eafe Mini Index Futures Mar13 Xnli | --- | --- | 2.09 |
| Sumitomo Mitsui Financial Group Inc | SMFNF | 39.55 | 2.07 |
| Mitsubishi UFJ Financial Group, Inc. | MBFJF | --- | 1.96 |
| AstraZeneca PLC | AZN | --- | 1.72 |
| Barclays PLC | BCLYF | 3.02 | 1.72 |
| Royal Dutch Shell PLC Class A | RYDAF | -0.16 | 1.65 |
| Tate & Lyle PLC | TATE | --- | 1.64 |
